272 related articles for article (PubMed ID: 18350600)
1. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.
Breuhahn K; Schirmacher P
World J Gastroenterol; 2008 Mar; 14(11):1690-8. PubMed ID: 18350600
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
4. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
[TBL] [Abstract][Full Text] [Related]
5. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
6. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.
Dransfield DT; Cohen EH; Chang Q; Sparrow LG; Bentley JD; Dolezal O; Xiao X; Peat TS; Newman J; Pilling PA; Phan T; Priebe I; Brierley GV; Kastrapeli N; Kopacz K; Martik D; Wassaf D; Rank D; Conley G; Huang Y; Adams TE; Cosgrove L
Mol Cancer Ther; 2010 Jun; 9(6):1809-19. PubMed ID: 20515953
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
10. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
Wu J; Zhu AX
J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
[TBL] [Abstract][Full Text] [Related]
11. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
[TBL] [Abstract][Full Text] [Related]
12. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
13. The IGF axis and hepatocarcinogenesis.
Scharf JG; Dombrowski F; Ramadori G
Mol Pathol; 2001 Jun; 54(3):138-44. PubMed ID: 11376124
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development.
Qiu LW; Yao DF; Zong L; Lu YY; Huang H; Wu W; Wu XH
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):406-11. PubMed ID: 18693177
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
[TBL] [Abstract][Full Text] [Related]
16. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.
Cantarini MC; de la Monte SM; Pang M; Tong M; D'Errico A; Trevisani F; Wands JR
Hepatology; 2006 Aug; 44(2):446-57. PubMed ID: 16871543
[TBL] [Abstract][Full Text] [Related]
17. Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells.
Jia S; Du Z; Jiang H; Huang X; Chen Z; Chen N
Oncol Rep; 2015 Jul; 34(1):511-7. PubMed ID: 25998745
[TBL] [Abstract][Full Text] [Related]
18. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
[TBL] [Abstract][Full Text] [Related]
19. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of growth factor signaling in human hepatocellular carcinoma.
Breuhahn K; Longerich T; Schirmacher P
Oncogene; 2006 Jun; 25(27):3787-800. PubMed ID: 16799620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
